Moderna Wins COVID Shot Patent Case vs. Pfizer-BioNTech In Europe

Moderna said that the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech, Reuters reported.

Pfizer and BioNTech have countersued, alleging that Moderna's patent is invalid after the companies' rival vaccines generated billions in revenues during the pandemic. I Photo: Moderna

The company has been locked in a legal battle with Pfizer-BioNTech over their COVID shot Comirnaty after suing them in 2022 for allegedly copying its mRNA technology.

Pfizer and BioNTech have countersued, alleging that Moderna's patent is invalid after the companies' rival vaccines generated billions in revenues during the pandemic. Pfizer said it was disappointed and would consider all legal options and may appeal the decision.

“Irrespective of the outcome of this legal matter, we will continue to manufacture and supply the Pfizer-BioNTech COVID-19 vaccine," Pfizer told Reuters.

BioNTech said the patent office's decision to maintain Moderna's European patent "does not change our unwavering and unequivocal stance that this patent is invalid." Pfizer, BioNTech, and Moderna are also involved in parallel proceedings related to their patents in Germany, the Netherlands, Belgium, England, and the US.